Chronic Lyme Disease Treatment: What the Evidence Shows Beyond Antibiotics

Chronic Lyme disease treatment that the evidence supports targets symptoms and immune dysregulation, not a lingering infection: four placebo-controlled trials (Klempner 2001, Krupp 2003, Fallon 2008, Berende 2016) found that extended antibiotics gave no lasting benefit over placebo. The CDC reports that most people with post-treatment Lyme disease syndrome (PTLDS) improve over time, and a plan built on symptom management, a careful search for other causes and selected off-label options such as low-dose naltrexone (LDN) is the most defensible approach.

Few topics in medicine generate as much controversy, confusion, and patient frustration as chronic Lyme disease. Patients with debilitating symptoms after Lyme infection are caught between a mainstream medical establishment that often dismisses their complaints and an alternative community that pushes treatments with limited evidence and real risks. Neither position serves patients well.

The sections below set out what the trials show, where the scientific debate is legitimate, and which treatment approaches have the most rational basis for the real syndrome that underlies most “chronic Lyme” presentations. For the full overview of Lyme disease management, see our Lyme disease guide.

Defining the Problem: PTLDS vs. “Chronic Lyme”

Post-treatment Lyme disease syndrome (PTLDS) is the term used by the IDSA (Infectious Diseases Society of America) to describe the subset of patients who complete standard antibiotic treatment for confirmed Lyme disease and continue to have symptoms for more than 6 months. The IDSA position is that PTLDS does not represent ongoing active infection with Borrelia burgdorferi in most cases. The CDC uses the same term and states that the cause is currently unknown.

“Chronic Lyme disease” is the term used by ILADS (International Lyme and Associated Diseases Society) and patient advocates, which frames the syndrome as indicating persistent active infection requiring ongoing antibiotic treatment. The evidence base for this framing is weak, and the treatment approaches it implies have been tested and found wanting in controlled trials.

These labels matter because they drive treatment decisions. Patients who receive a “chronic Lyme” framing often end up on prolonged IV antibiotic courses with meaningful risks and no demonstrated benefit. Understanding what the trials actually showed is essential.

How common are lingering symptoms after Lyme disease?

Estimates vary with the definition used. Johns Hopkins researchers (Feng et al., 2020) cite about 10 to 20% of treated patients. The CDC’s page on chronic symptoms and Lyme disease points to studies showing that, 6 months after treatment, fatigue, body aches and thinking problems are 5 to 10% more common in people who had Lyme disease than in people who did not. Either way, the group is large enough that every clinician in an endemic area will see it.

What is the standard treatment for Lyme disease?

Standard Lyme disease treatment is a fixed course of antibiotics matched to the stage of infection. The 2020 IDSA, AAN and ACR guideline (Lantos et al., published in Clinical Infectious Diseases in 2021) recommends 10 days of doxycycline, or 14 days of amoxicillin or cefuroxime, for the erythema migrans rash of early Lyme disease. Lyme arthritis is treated with 28 days of oral antibiotics, and neurologic Lyme disease and Lyme carditis usually with 14 to 21 days.

The same guideline recommends against extended antibiotic courses for persistent symptoms after this treatment, because of the trial evidence below. That is the point where most patients start searching for chronic Lyme disease treatment, and where care often stops. The Lyme disease treatment guide covers the acute stages in more detail.

What the Antibiotic Trials Found

Four well-designed randomized controlled trials have specifically tested prolonged antibiotic treatment in patients with persistent Lyme symptoms. The results are consistent: no trial found a durable benefit over placebo.

Klempner 2001 (New England Journal of Medicine, n=129)

Klempner and colleagues ran two parallel trials in 78 seropositive and 51 seronegative patients with persistent pain, neurocognitive symptoms or dysesthesia after treated Lyme disease. Patients received 30 days of IV ceftriaxone (2 g daily) followed by 60 days of oral doxycycline (200 mg daily), or matching placebos. The data and safety monitoring board stopped both trials after an interim analysis showed a meaningful difference was highly unlikely. According to the published results, 37% of seropositive patients on antibiotics improved, compared with 40% on placebo.

Krupp 2003 (Neurology, n=55)

Krupp et al. randomized patients with PTLDS and severe fatigue to 28 days of IV ceftriaxone versus placebo, in the trial known as STOP-LD (Study and Treatment of Post Lyme Disease). At the primary endpoint (6 months), the antibiotic group showed improvement in fatigue scores compared to placebo, but no improvement in cognitive functioning and no change in a laboratory marker of persistent infection. Four patients had adverse events that required hospitalization, three of them in the placebo group. The authors concluded that the results do not support additional IV ceftriaxone, because fatigue is a nonspecific symptom and treatment carried risk.

Fallon 2008 (Neurology, n=37)

Fallon et al. gave 10 weeks of IV ceftriaxone to patients with PTLDS and objective memory impairment. At 12 weeks, the antibiotic group showed cognitive improvement. But at 24 weeks, after antibiotics stopped, the cognitive gains had not been sustained, and there was no lasting cognitive benefit over placebo. Some patients with severe pain and fatigue kept improvements in pain and physical function. Adverse events from the drug or the PICC line occurred in 6 of 23 patients on ceftriaxone and 1 of 14 on placebo, according to the trial report.

PLEASE Trial 2016 (New England Journal of Medicine, n=281)

The PLEASE trial, led by Berende and colleagues in the Netherlands, was the largest and most rigorous. All 281 patients received 2 weeks of open-label IV ceftriaxone, then were randomized to 12 weeks of doxycycline, clarithromycin plus hydroxychloroquine, or placebo. Quality-of-life scores did not differ between groups at the end of treatment or at later visits, according to the NEJM report. All groups improved somewhat from baseline, and four serious drug-related adverse events occurred during the ceftriaxone phase. This trial is sometimes mislabeled as STOP-LD, which is the name of the Krupp trial.

Taken together, these four trials show that prolonged antibiotics do not produce sustained benefit in PTLDS and carry real procedural and microbiological risks. This does not mean patients are not suffering. It means their suffering is not being driven by active bacterial replication that antibiotics can address.

What Is Actually Causing PTLDS Symptoms?

The most plausible mechanisms are post-infectious immune dysregulation and, in some cases, autoimmunity. Borrelia infection triggers a robust immune response. In some patients, this response persists after the bacteria are cleared, driven by molecular mimicry (immune cells attacking host tissue that resembles bacterial antigens), residual bacterial debris, or aberrant immune activation that becomes self-sustaining.

A 2022 study in Cell Reports Medicine (Clarke, Aucott, Ma’ayan and colleagues at Johns Hopkins and Mount Sinai) profiled blood immune cells from 152 people with post-treatment Lyme disease using RNA sequencing. Most had an inflammatory gene expression signature that was distinct from both uninfected controls and people with acute Lyme disease, according to the published study. That pattern supports the post-infectious dysregulation hypothesis, although it is not yet a validated diagnostic test.

A subset of patients with post-Lyme arthritis have been found to have T cell and antibody responses to host proteins including MMP-10, a matrix metalloproteinase expressed in joint tissue (Crowley et al., Journal of Autoimmunity, 2016). In these patients, the joint inflammation continues after infection clearance because the immune system is attacking host tissue, not bacteria. Rheumatologists treat this autoimmune-dominant subset of arthritis with hydroxychloroquine and disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, which the IDSA guideline favors over further antibiotics.

What else can look like chronic Lyme disease?

Persistent fatigue, pain and brain fog are not specific to Lyme disease, so a careful workup looks for other causes before settling on PTLDS. Conditions worth ruling out include thyroid disease, sleep apnea, depression, anemia, inflammatory arthritis, multiple sclerosis and tick-borne co-infections such as babesiosis and anaplasmosis. Many patients also meet criteria for fibromyalgia or ME/CFS, which changes the treatment plan. Our posts on Lyme co-infections and Lyme disease testing explain how those questions are usually answered.

Emerging and Experimental Approaches

None of the options in this section has a completed randomized trial in PTLDS. Most are cash pay and off label, and the evidence ranges from mechanistic reasoning to small case series. They are described here so patients can weigh them honestly.

Low-Dose Naltrexone (LDN)

LDN (1.5-4.5mg daily) reduces neuroinflammation by modulating microglial and astrocyte activation, which is directly relevant to the central sensitization and cognitive symptoms seen in PTLDS. Given the overlap between PTLDS symptom profiles and conditions where LDN has a stronger evidence base (ME/CFS, fibromyalgia, autoimmune conditions), it has a rational mechanistic basis for trial in PTLDS patients.

Dedicated LDN trials in PTLDS do not yet exist; the support comes from clinician experience and patient reports rather than controlled data. LDN is generally well tolerated, with vivid dreams and sleep disturbance the most common complaints, which makes it a reasonable option for clinicians managing PTLDS who are willing to use off-label treatments. The LDN guide covers dosing schedules and interactions, including the conflict with opioid pain medicines.

Herbal Protocols

Feng, Zhang and colleagues at the Johns Hopkins Bloomberg School of Public Health (Frontiers in Medicine, 2020) tested 12 botanical medicines and three other natural agents against Borrelia in the lab. Seven extracts, including cryptolepis, black walnut, Japanese knotweed, sweet wormwood and cat’s claw, showed good activity against non-growing stationary-phase Borrelia compared with doxycycline and cefuroxime, and only cryptolepis eradicated the culture on subculture. This work was entirely in vitro; no human trial has been completed, and in vitro activity does not predict in vivo clinical benefit.

Buhner’s herbal protocol (centered on Japanese knotweed/resveratrol, cat’s claw, andrographis) is widely used in the integrative Lyme community. In the same Johns Hopkins screen, andrographis had little or no activity against stationary-phase Borrelia. Some herbs in this protocol have real anti-inflammatory effects that may provide symptomatic relief independent of any anti-Borrelia activity. Resveratrol, for example, has demonstrated neuroprotective and anti-inflammatory properties in multiple non-Lyme research contexts. Patients using these protocols should be aware that the evidence is mechanistic and in vitro, not clinical trial data.

Disulfiram

Disulfiram (Antabuse), typically used for alcohol use disorder, was found in 2016 in vitro research by Pothineni and colleagues to have activity against Borrelia, including stationary-phase persister forms that are not eliminated by standard antibiotics. This generated significant interest in the ILADS community.

A retrospective review from one practice (Gao, Liegner and colleagues, Antibiotics, 2020) followed 67 patients and reported that most described some benefit. In the high-dose group, the same review recorded fatigue in 66.7%, psychiatric symptoms in 48.5% and peripheral neuropathy in 27.3% of patients. No randomized trial has been completed. The in vitro data is interesting but far from a clinical endorsement. Disulfiram has a real risk profile and should not be used outside of monitored clinical research settings.

Ozone Therapy

Ozone therapy is used at some integrative clinics for PTLDS on the rationale that ozone has antimicrobial properties and may modulate immune function. The clinical evidence in Lyme is limited to case reports and anecdotal series. There are no randomized controlled trials. The mechanism is plausible in theory (ozone has documented effects on oxidative stress and immune signaling), but translating in vitro antimicrobial activity to clinical benefit in a complex post-infectious syndrome is a large leap that has not been validated. The FDA has not approved ozone for any medical use, and our post on ozone therapy for Lyme disease covers the safety questions in more depth.

Hyperbaric Oxygen Therapy (HBOT)

HBOT has been proposed for chronic Lyme on both antimicrobial grounds (Borrelia is microaerophilic and may be sensitive to hyperoxia) and neurological grounds (HBOT reduces neuroinflammation and promotes tissue repair). Human data consists of case reports and small uncontrolled series reporting symptom improvement. No randomized trial has been completed in PTLDS. Given the evidence from long COVID brain fog research (Zilberman-Itskovich et al., Scientific Reports, 2022, a randomized controlled trial), HBOT may have a rational role for the neurological component of PTLDS, but this is extrapolation, not direct evidence. Lyme disease is not on the FDA-cleared list of HBOT indications, so it is typically cash pay.

IV Vitamin C

High-dose intravenous vitamin C has been proposed based on antioxidant and immune-modulating properties. The evidence in PTLDS is anecdotal. IV vitamin therapy is used across integrative medicine practices for various chronic conditions, and while it is generally well-tolerated, the specific evidence in Lyme is essentially absent. People with G6PD deficiency or a history of kidney stones need screening first, because high doses can cause harm in both groups. The rationale is that oxidative stress and immune dysregulation are both present in PTLDS, and IV vitamin C addresses both. This is mechanistically reasonable but clinically unvalidated in this population.

Evidence Summary

Extended antibiotics have the strongest evidence of any chronic Lyme disease treatment, and that evidence is negative. Every other option rests on mechanism, lab work or small uncontrolled reports, with the exception of DMARDs for the autoimmune arthritis subgroup.

What Patients Deserve to Know

The PTLDS patient population is real, their symptoms are real, and they often receive inadequate care from clinicians who dismiss them once standard antibiotic courses are complete. That is a genuine problem in medicine.

But the response to inadequate care should not be indefinite antibiotic treatment that the evidence shows does not work and carries real harms. Patients who cycle through prolonged antibiotic courses often feel temporarily better (a placebo effect that clinical trials have documented), worsen when antibiotics stop, and then attribute worsening to return of infection rather than loss of the placebo response. This cycle does not serve them.

The most productive frame is: you have a post-infectious syndrome with a real immune and neurological basis. The bacteria are almost certainly gone. The treatment target is the dysregulated immune system and its downstream effects, not an ongoing infection. With that frame, immune-modulating approaches (LDN, hydroxychloroquine for the autoimmune subset, anti-inflammatory lifestyle interventions) and symptom-management approaches (pacing, sleep optimization, pain management) become the rational treatment priorities.

If you are seeing a clinician who is only willing to prescribe more antibiotics or who dismisses all your symptoms as psychological, consider finding a physician with expertise in post-infectious syndromes, which increasingly includes long COVID specialists who are developing relevant expertise in this disease category. The same principles guide chronic pain treatment and ME/CFS treatment, which many PTLDS patients end up drawing on.

What does a symptom-focused plan for PTLDS include?

1. A review of the original diagnosis and treatment, and testing for co-infections and other conditions that mimic PTLDS.
2. Sleep assessment and treatment, including screening for sleep apnea.
3. Activity pacing that keeps exertion below the level that triggers a crash, then builds gradually.
4. Pain management that avoids long-term opioids, such as graded exercise where tolerated, physical therapy and non-opioid medicines.
5. Cognitive support for brain fog, including treatment of depression or anxiety when present.
6. A defined trial of one off-label option at a time, such as LDN, with a set review date to judge whether it helped.

Who treats chronic Lyme disease?

Several clinician types treat persistent symptoms after Lyme disease, and they often disagree. Infectious disease specialists usually follow the IDSA guideline and focus on confirming the diagnosis and ruling out ongoing infection. Rheumatologists manage post-Lyme arthritis and autoimmune overlap, and neurologists assess neuropathy, cognitive complaints and nervous system involvement.

Integrative and functional medicine physicians, and clinicians who follow ILADS guidance (sometimes called Lyme-literate doctors, or LLMDs), are more likely to offer off-label options such as LDN, HBOT, IV therapies and herbal protocols. A well run practice of any kind documents the diagnosis, explains which parts of a plan are off label, and sets measurable goals rather than open-ended courses.

How to find a clinic for persistent Lyme symptoms

The directory of Lyme disease treatment clinics lists practices that offer care for Lyme disease and its aftermath, and state pages such as Lyme disease clinics in New York, Massachusetts and Maryland narrow the search to endemic areas. Listing order is not a paid ranking, Featured slots are labeled and capped, and Verified means a clinic has passed credential checks rather than paid for placement. Regenerated.com is free for patients, and inclusion in the directory is not an endorsement.

Cost is a practical part of the decision. Guideline antibiotic treatment and specialist visits are usually covered by insurance, while LDN prescriptions are often inexpensive, and HBOT, ozone and IV therapies for Lyme are typically cash pay because they are off label for this use. Ask for a written plan and fee estimate before starting, and read the guide to Featured, Verified and organic listings to understand what each label on a clinic profile means.

Questions to ask a clinic before starting treatment

• How do you confirm that my symptoms are related to Lyme disease, and what else have you ruled out?
• Which parts of this plan are guideline care, and which are off label or experimental?
• What published evidence supports each treatment you are proposing for my symptoms?
• How will we measure whether it is working, and when will we stop if it is not?
• What are the risks, what will it cost, and what will my insurance cover?

Frequently asked questions

What is the best treatment for chronic Lyme disease?

No single treatment works for everyone with chronic Lyme disease, which most researchers call post-treatment Lyme disease syndrome (PTLDS). The approach with the most support combines symptom management (sleep, pacing, pain care), a search for other causes and co-infections, and selected off-label options such as low-dose naltrexone. Four placebo-controlled trials found that extended antibiotics gave no lasting benefit, so the IDSA, AAN and ACR guideline recommends against them.

Can chronic Lyme disease go away on its own?

Yes, for most people symptoms ease with time. The CDC reports that patients with prolonged symptoms after Lyme disease usually get better without additional antibiotics, though it can take many months to feel completely well. Recovery is often uneven, with good and bad weeks. Treating sleep problems, pacing activity and managing pain can make that period easier while the immune system settles.

Do long-term antibiotics help chronic Lyme symptoms?

Long-term antibiotics have not shown lasting benefit for persistent Lyme symptoms in controlled trials. Klempner (2001), Krupp (2003), Fallon (2008) and the PLEASE trial (Berende, 2016) compared extended antibiotics with placebo, and none found a sustained improvement in quality of life or cognition. Fallon found short-term cognitive gains that faded after treatment stopped. IV courses also carried risks, including PICC line complications and serious drug reactions.

Is low-dose naltrexone used for chronic Lyme disease?

Yes, low-dose naltrexone (LDN) is prescribed off label for chronic Lyme symptoms, usually at 1.5 to 4.5 mg daily. The rationale is that LDN calms microglial activation and neuroinflammation, which may drive fatigue, pain and brain fog in PTLDS. No randomized trial in PTLDS has been published, so the support is indirect, drawn from fibromyalgia and ME/CFS. LDN is generally well tolerated but cannot be combined with opioid medicines.

Does insurance cover chronic Lyme disease treatment?

Insurance usually covers guideline care for Lyme disease, including diagnostic testing, standard antibiotic courses and visits with infectious disease specialists, rheumatologists and neurologists. Coverage for chronic Lyme disease treatment beyond that is limited. HBOT, ozone therapy, IV vitamin therapy and herbal protocols are generally cash pay because they are off label for Lyme disease. Ask any clinic for a written plan and fee estimate before starting.

What kind of doctor should I see for post-treatment Lyme disease syndrome?

Start with a primary care physician or an infectious disease specialist who can confirm the original diagnosis and rule out ongoing infection or other conditions. A rheumatologist is the right choice for joint swelling or suspected autoimmune arthritis, and a neurologist for numbness, nerve pain or memory problems. Integrative physicians can coordinate off-label options, ideally while being clear about which treatments have trial evidence.

---

Related Reading

• Arthritis Guide: Rheumatoid Arthritis and Osteoarthritis
• Brain Fog: Causes, Testing, Treatment, and When It Signals Something Deeper
• Fibromyalgia: Causes, Diagnosis, and the Complete Treatment Guide
• Hyperbaric Oxygen Therapy (HBOT): How It Works, What It Treats, and What the Evidence Shows
• Long COVID: Symptoms, Causes, Treatment, and What Regenerative Medicine Offers
• Low Dose Naltrexone (LDN): A Comprehensive Guide to Uses, Dosing, Evidence, and Side Effects